Mycobacteria and Crohn's disease: The endless story

Digestive and Liver Disease

Volumn 39, Issue 5, 2007, Pages 452-454

  Prantera, C ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIMYCOBACTERIAL AGENT; BACTERIUM ANTIBODY; CELL RECEPTOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; COLON BIOPSY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; INTESTINE MUCOSA; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM PARATUBERCULOSIS; PARATUBERCULOSIS; ULCERATIVE COLITIS;

EID: 33947728999     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.02.002     Document Type: Note

References (22)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
2. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
3. Prantera C., and Scribano M.L. Crohn's disease: the case for bacteria. Ital J Gastroenterol Hepatol 31 (1999) 244-246
4. Gray J.R., and Rabeneck L. Atypical Mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol 84 (1989) 1521-1524
5. Chiodini R.J., van Kruiningen H.J., Thayer W.K., Merkal R.S., and Coutu J.A. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 29 (1984) 1073-1079
6. Graham D.Y., Markesich D.C., and Yoshimura H.H. Mycobacteria and inflammatory bowel disease. Results of culture. Gastroenterology 92 (1987) 436-442
7. Kobayashi K., Blaser M.J., and Brown W.R. Immunohistochemical examination for Mycobacteria in intestinal tissues from patients with Crohn's disease. Gastroenterology 96 (1989) 1009-1015
8. Bull T.J., McMinn E.J., Sidi-Boumedine K., Skull A., Durkin D., Neild P., et al. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol 41 (2003) 2915-2923
9. Swidsinski A., Ladhoff A., Pernthaler A., Swidsinski S., Loening-Baucke V., Ortner M., et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122 (2002) 44-54
10. Cho S.-N., Brennan P.J., Yoshimura H.H., Korelitz B.I., and Graham D.Y. Mycobacterial etiology of Crohn's disease: serologic study using common mycobacterial antigens and a species-specific glycolipid antigen from Mycobacterium paratuberculosis. Gut 27 (1986) 1353-1356
11. Blaser M.J., Miller R.A., Lather J., and Singleton J.W. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 87 (1984) 888-894
12. Kobayashi K., Brown W.R., Brennan P.J., and Blaser M.J. Serum antibodies to mycobacterial antigens in active Crohn's disease. Gastroenterology 94 (1988) 1404-1411
13. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126 (2004) 1504-1517
14. Tysk C., Lindberg E., Jarnerot G., and Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29 (1998) 990-996
15. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
16. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 (1995) 561-572
17. Senaldi G., and Yin S. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 157 (1996) 5022-5026
18. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
19. Borgaonkar M.R., MacIntosh D.G., and Fardy J.M. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 95 (2000) 725-729
20. Prantera C., Kohn A., Mangiarotti R., Andreoli A., and Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double blind trial with a multiple antibiotic regimen. Am J Gastroenterol 89 (1994) 513-518
21. Borody T.J., Bilkey S., Wettstein A.R., Leis S., Pang G., and Tye S. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig Liver Dis (2007) 39
22. Polymeros D., Bogdanos D.P., Day R., Arioli D., Vergani D., and Forbes A. Does cross-reactivity between Mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease?. Gastroenterology 131 (2006) 85-96